145 related articles for article (PubMed ID: 3332186)
1. Preparative regimens for marrow transplantation containing busulphan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis.
Atkinson K; Biggs J; Noble G; Ashby M; Concannon A; Dodds A
Bone Marrow Transplant; 1987 Dec; 2(4):385-94. PubMed ID: 3332186
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.
Bandini G; Belardinelli A; Rosti G; Calori E; Motta MR; Rizzi S; Benini C; Tura S
Bone Marrow Transplant; 1994 May; 13(5):577-81. PubMed ID: 8054910
[TBL] [Abstract][Full Text] [Related]
3. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation.
Morgan M; Dodds A; Atkinson K; Szer J; Downs K; Biggs J
Br J Haematol; 1991 Apr; 77(4):529-34. PubMed ID: 2025579
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome.
Rubin CM; Mick R; Johnson FL
Bone Marrow Transplant; 1996 Sep; 18(3):533-40. PubMed ID: 8879614
[TBL] [Abstract][Full Text] [Related]
5. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
6. Bladder irrigation does not prevent haemorrhagic cystitis in bone marrow transplant recipients.
Atkinson K; Biggs JC; Golovsky D; Concannon A; Dodds A; Downs K; Ashby M
Bone Marrow Transplant; 1991 May; 7(5):351-4. PubMed ID: 2070143
[TBL] [Abstract][Full Text] [Related]
7. [The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
Zhu K; Xu Y; Wu D; Xu X; Huang L
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):403-5. PubMed ID: 11877010
[TBL] [Abstract][Full Text] [Related]
8. Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy.
Thomas AE; Patterson J; Prentice HG; Brenner MK; Ganczakowski M; Hancock JF; Pattinson JK; Blacklock HA; Hopewell JP
Bone Marrow Transplant; 1987 Apr; 1(4):347-55. PubMed ID: 3139113
[TBL] [Abstract][Full Text] [Related]
9. Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience.
Flowers ME; Doney KC; Storb R; Deeg HJ; Sanders JE; Sullivan KM; Bryant E; Witherspoon RP; Appelbaum FR; Buckner CD
Bone Marrow Transplant; 1992 Mar; 9(3):167-73. PubMed ID: 1511254
[TBL] [Abstract][Full Text] [Related]
10. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
11. Busulfan-containing pre-transplant regimens for the treatment of solid tumors.
Ghalie R; Reynolds J; Valentino LA; Manson S; Korenblit AD; Feingold JM; Adler SS; Pruett J; Kaizer H
Bone Marrow Transplant; 1994 Sep; 14(3):437-42. PubMed ID: 7994269
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
[TBL] [Abstract][Full Text] [Related]
13. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
15. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children.
Shaw PJ; Hugh-Jones K; Hobbs JR; Downie CJ; Barnes R
Bone Marrow Transplant; 1986 Dec; 1(2):193-200. PubMed ID: 3332132
[TBL] [Abstract][Full Text] [Related]
16. Busulphan and melphalan prior to autologous bone marrow transplantation.
Srivastava A; Bradstock KF; Szer J; de Bortoli L; Gottlieb DJ
Bone Marrow Transplant; 1993 Oct; 12(4):323-9. PubMed ID: 8275031
[TBL] [Abstract][Full Text] [Related]
17. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
[TBL] [Abstract][Full Text] [Related]
20. Association of busulfan area under the curve with veno-occlusive disease following BMT.
Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
